TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03119363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AYO light glasses (Experimental)
Description: The AYO does not contain UV or infra-red light; the light spectrum begins at approximately 420nm. The circadian-effective AYO is programed at over 100 lux with 470nm frequency and irradiance of 250 qW/cm2, which is 100% intensity level. Irradiance over lux itself with AYO light glasses is believed to be more representative due to light frequency and proximity to the eye. Traditional Lightbox usual measure is Lux , AYO can be seen as comparable to 1,000 lux light box. The device is classified as a device that is safe for the eyes in accordance with the international standard IEC 62471 and is independently certified by TÜV Rheinland. AYO complies with the EU's CE marking (CE EMC EN 55014, EN 61000-4-3) as well as other national regulatory directives. AYO also complies with the United States of America's FCC marking (FCC Title 47, Chapter 1, Part 15, Class B FCC VOC: 47 CFR PART 15 OCT, 2016. CLASS B ANSI C 63.4: 2014) as well as other national marking regulatory directives.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AYO light glasses (Comparator)
Description: The comparison group will wear the same AYO glasses, but with a circadian ineffective (sham) light. The circadian-ineffective (sham) is programed at 1% intensity, therefore according to our calculation and checks it is below circadian threshold of 2 lux as specified.
Study: NCT04612894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Apatinib
Description: All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Perform surgery if operable after neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core needle biopsy
Description: Perform core needle biopsy if inoperable after neoadjuvant therapy
Study: NCT00623506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)
Study: NCT02379546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index monitoring
Description: Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index monitoring
Description: Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
Study: NCT01725854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response training
Description: Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
Study: NCT01936753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trained Mentor Mother and Supervisor
Description: Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
Study: NCT05218837

Intervention type: OTHER
Intervention: Vaginal birth
Description: Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.

Intervention type: OTHER
Intervention: Vaginal birth
Description: Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.

Intervention type: OTHER
Intervention: Vaginal birth
Description: Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.
Study: NCT03018041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor
Description: As described in Arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: As described in Arms.
Study: NCT06405867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed cord clamping (> 60 sec)
Description: In the DCC group, cord pulse was checked without allowing clamping. Waited until the cord pulse stopped. It was wrapped in a sterile and warm cloth and dried. The cord was clamped when the pulse stopped. The cord clamping time was noted on the case report form. In DCC, the baby was placed on the mother's legs in cesarean section (C/S) births and on the mother's mons pubis region in normal vaginal births. The baby was administered a routine delivery room neonatal resuscitation program (NRP) by the pediatrician. After cord clamping, the baby was handed over to the pediatric team.
Study: NCT03003988

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Creatine monohydrate (6.0 g) + dextrose (0.5 g)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine nitrate
Description: Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (6.5 g dextrose)
Study: NCT02882230

Intervention type: DRUG
Intervention: prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir
Description: chemical dosage ARV
Study: NCT02899286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-BCT-100
Description: PEGylated recombinant human arginase
Study: NCT01679262

Intervention type: DEVICE
Group type: OTHER
Intervention: Guedel type color-coded OPAs
Description: The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
Study: NCT02860884

Intervention type: PROCEDURE
Intervention: liver biopsy

Intervention type: PROCEDURE
Intervention: liver biopsy
Study: NCT00107575

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment (ST)
Description: Behavioral smoking cessation counseling and nicotine patch.
Study: NCT03714516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological internet intervention
Description: The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
Study: NCT00738127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Description: Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Description: Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.
Study: NCT03754608

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI including cf-MRI, DTI, ASL and CVR.
Description: A paradigm developed at Yale University called Cognitive Predictive Modelling which takes connectivity data and reduces it to two smaller network which predict higher and lower performance in a particular task for which these networks have been optimized. This will be supplemented by MRI vascular measures.
Study: NCT02860884

Intervention type: OTHER
Intervention: infrared spectroscopy

Intervention type: OTHER
Intervention: infrared spectroscopy
Study: NCT01872741

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minipterional craniotomy
Description: Minipterional craniotomy approach for ruptured and unruptured aneurysms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minipterional craniotomy
Description: Minipterional craniotomy approach for ruptured and unruptured aneurysms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pterional craniotomy
Description: Pterional craniotomy approach for ruptured and unruptured aneurysm
Study: NCT04015388

Intervention type: DEVICE
Intervention: iPro Continuous Glucose Monitoring
Description: iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.
Study: NCT02893358

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
Study: NCT03690778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Rosuvastatin seperately
Description: administration of Metformin and Rosuvastatin seperately

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Rosuvastatin seperately
Description: administration of Metformin and Rosuvastatin seperately
Study: NCT01872741

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pterional craniotomy
Description: Pterional craniotomy approach for ruptured and unruptured aneurysm
Study: NCT02481726

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG
Study: NCT03772561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363+Olaparib+Durvalumab
Description: Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities.
Study: NCT00412698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant
Description: Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.~White film-coated tablets, for oral administration containing 20 mg of active rimonabant
Study: NCT01789957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: 4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
Study: NCT00412698

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
Study: NCT01290172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Somatostatin
Description: 6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of placebo
Description: The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy.
Study: NCT02812433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ora-Blend
Description: Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
Study: NCT00865007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monotherapy (Lopinavir/ritonavir)
Description: NRTI sparing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy (Lopinavir/ritonavir)
Description: NRTI sparing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy (Lopinavir/ritonavir) + ABC/3TC
Description: NRTI sparing regimen
Study: NCT03605524

Intervention type: OTHER
Group type: OTHER
Intervention: Sensory training
Description: 12 weeks sensory training
Study: NCT00003098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fat reduction with increased fiber
Description: Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fat reduction without increased fiber
Description: Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
Study: NCT03579134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: partial overlay denture
Description: removable appliance similar to a removable partial denture but with overlay occluslal rests covering the full occlusal surface of the remaining posterior teeth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fixed temporary crowns
Description: fixed crowns made from temporary material placed to the newly altered vertical dimension
Study: NCT05299567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Placebo with the same color and size than azithromycin tree days a wek for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Placebo with the same color and size than azithromycin tree days a wek for 6 months
Study: NCT03329040

Intervention type: OTHER
Intervention: No Intervention.
Description: No intervention.
Study: NCT01481857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental trunk exercise associated with proprioception
Description: Proprioceptive exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental trunk exercise
Description: Segmental trunk exercise
Study: NCT02181296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Study: NCT04512326

Intervention type: PROCEDURE
Intervention: Total or Subtotal colectomy
Description: Total or subtotal colectomy (emergent or elective) with primary anastomosis (ileorectal or ileosigmoid)
Study: NCT01888341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin Capsules,20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin Capsules,20 mg
Study: NCT00809237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib, Hydroxychloroquine
Description: Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
Study: NCT00668720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation (Magstim rapid2)
Description: Neuronavigated rTMS will be applied bilaterally to the auditory cortices, which will be identified through a structural MRI scan. Stimulation will be performed with 1 Hz frequency and an intensity of 110% motor threshold for 2000 stimuli (32 minutes) on each side, on five subsequent days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The official sham stimulator for the magstim rapid2 will be used. Sham stimulation will follow the same placement protocol and will also last 2x32 minutes on five subsequent days
Study: NCT00466895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
Study: NCT01853241

Intervention type: PROCEDURE
Intervention: Single Balloon
Description: All patients in this group will undergo single balloon enteroscopy
Study: NCT02049697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-JNJ-39823277
Description: Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution.
Study: NCT01853241

Intervention type: PROCEDURE
Intervention: Spirus
Description: All patients in this group will undergo Spirus Enteroscopy
Study: NCT02857491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: intravitreal injection of 0.5 mg ranibizumab before vitrectomy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham
Description: sham intravitreal injection before vitrectomy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pars plana vitrectomy
Description: surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pars plana vitrectomy
Description: surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.